EGFR and non-small cell lung carcinoma: Among the 139 patients with EGFR-mutation-positive advanced NSCLC who received EGFR-TKI treatment, 97 had available FFPE tissue that could be analyzed for BIM deletion polymorphism and 96 had tissue samples allowing an analysis of BIM expression.